The first coronavirus vaccines are being approved around the world, with some countries already starting to immunize their populations.
Governments have had to think and act like investors during the development of the vaccine candidates during the year, attempting to anticipate which will prove safe and effective and then order it in sufficient quantity but without paying too much for an unapproved product.
Our table below details the orders lodged in some of the world's major markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze